Targeting integrin (alpha)v(beta)3 in the treatment of malignant glioma

靶向整合素（α）v（β）3治疗恶性胶质瘤

• 批准号: 214234
• 负责人: Franovic Aleksandra
• 金额: $ 10.93万
• 依托单位: University of California (San Diego)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-10-01 至 2013-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=214234&lang=en
• 关键词: Allosteric Raf Inhibitors; C-Raf; Cell Proliferation/Death Assays; Cell Signaling / Tumorigenic Mechanisms; Cilengitide; Glioblastoma Multiforme; Host-Tumor Interactions; Immunohistochemistry; Integrin Alpha V Beta 3; Orthotopic Brain Tumors

The most common form of brain cancer, glioblastoma multiforme (GBM), is highly aggressive, virtually untreatable and most often fatal. This is reflected in the median survival time of GBM patients which is in the range of 14 months with surgery and curre

多形性胶质母细胞瘤（GBM）是脑癌中最常见的一种，它具有很强的侵袭性，几乎无法治疗，而且通常是致命的。这反映在GBM患者的中位生存时间上，手术和治愈后的中位生存时间为14个月